United Therapeutics Corporation (NASDAQ:UTHR) has been assigned an average rating of “Hold” from the sixteen brokerages that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $127.80.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 3rd. TheStreet lowered United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, BidaskClub lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st.

In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of United Therapeutics Corporation stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the transaction, the director now owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,236 shares of United Therapeutics Corporation stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $131.62, for a total value of $162,682.32. Following the transaction, the chief executive officer now directly owns 1,376 shares in the company, valued at approximately $181,109.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,298 shares of company stock worth $2,322,339. Company insiders own 7.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd purchased a new position in United Therapeutics Corporation during the 2nd quarter valued at about $285,000. Ameritas Investment Partners Inc. grew its stake in United Therapeutics Corporation by 1.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,485 shares of the biotechnology company’s stock valued at $1,749,000 after acquiring an additional 231 shares in the last quarter. Nomura Holdings Inc. purchased a new position in United Therapeutics Corporation during the 2nd quarter valued at about $403,000. The Manufacturers Life Insurance Company grew its stake in United Therapeutics Corporation by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 66,372 shares of the biotechnology company’s stock valued at $8,611,000 after acquiring an additional 1,242 shares in the last quarter. Finally, Caxton Associates LP grew its stake in United Therapeutics Corporation by 27.3% during the 2nd quarter. Caxton Associates LP now owns 2,800 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 600 shares in the last quarter.

Shares of United Therapeutics Corporation (UTHR) traded down 1.13% during midday trading on Wednesday, reaching $120.15. 672,869 shares of the company were exchanged. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a market capitalization of $5.22 billion, a PE ratio of 13.93 and a beta of 1.49. The firm’s 50 day moving average is $124.03 and its 200-day moving average is $126.49.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.42 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post $10.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/11/united-therapeutics-corporation-uthr-receives-consensus-recommendation-of-hold-from-brokerages.html.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.